These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30070032)

  • 21. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial.
    Silber S; Windecker S; Vranckx P; Serruys PW;
    Lancet; 2011 Apr; 377(9773):1241-7. PubMed ID: 21459430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
    Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
    Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale and design of the clinical evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical trial).
    Mauri L; Leon MB; Yeung AC; Negoita M; Keyes MJ; Massaro JM
    Am Heart J; 2011 May; 161(5):807-14. PubMed ID: 21570508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zotarolimus-eluting Resolute Integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis.
    Patra S; Chakraborty RN; Pande A; Banerjee S; Jena M; Mandal PC; De SK; Khan A; Das SS; Ghosh D; Nag R
    Cardiovasc Revasc Med; 2017; 18(3):160-164. PubMed ID: 28017259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.
    Leon MB; Mauri L; Popma JJ; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; McLaurin BT; Solomon SL; Douglas JS; Ball MW; Caputo RP; Jain A; Tolleson TR; Reen BM; Kirtane AJ; Fitzgerald PJ; Thompson K; Kandzari DE;
    J Am Coll Cardiol; 2010 Feb; 55(6):543-54. PubMed ID: 20152559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease.
    Tada T; Byrne RA; Cassese S; King L; Schulz S; Mehilli J; Schömig A; Kastrati A
    Am Heart J; 2013 Jan; 165(1):80-6. PubMed ID: 23237137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of everolimus-eluting and resolute zotarolimus-eluting stents in the treatment of coronary bifurcations.
    Ferrarello S; Costopoulos C; Latib A; Naganuma T; Sticchi A; Figini F; Basavarajaiah S; Carlino M; Chieffo A; Montorfano M; Kawaguchi M; Naim C; Giannini F; Colombo A
    J Invasive Cardiol; 2013 Sep; 25(9):436-40. PubMed ID: 23995715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
    Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
    JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.
    Teeuwen K; Van den Branden BJ; Koolen JJ; van der Schaaf RJ; Henriques JP; Tijssen JG; Kelder JC; Vermeersch PH; Rensing BJ; Suttorp MJ
    EuroIntervention; 2015 Mar; 10(11):1272-5. PubMed ID: 25136884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unrestricted use of endeavor resolute zotarolimus-eluting stent in daily clinical practice: a prospective registry.
    Galasso G; Piccolo R; Cassese S; Esposito G; Cirillo P; Leosco D; Rapacciuolo A; Sirico D; De Biase C; Niglio T; Piscione F
    J Invasive Cardiol; 2012 Jun; 24(6):251-5. PubMed ID: 22684376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does stent strut design impact clinical outcomes: comparative safety and efficacy of Endeavor Resolute versus Resolute Integrity zotarolimus-eluting stents.
    Di Santo P; Simard T; Ramirez FD; Pourdjabbar A; Harnett DT; Singh K; Moreland R; Chong AY; Dick A; Labinaz M; Froeschl M; Froeschl M; Le May MR; So DY; Hibbert B
    Clin Invest Med; 2015 Oct; 38(5):E296-304. PubMed ID: 26854891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
    Lee JM; Park KW; Han JK; Yang HM; Kang HJ; Koo BK; Bae JW; Woo SI; Park JS; Jin DK; Jeon DW; Oh SK; Park JS; Kim DI; Hyon MS; Jeon HK; Lim DS; Kim MG; Rha SW; Her SH; Hwang JY; Kim S; Choi YJ; Kang JH; Moon KW; Jang Y; Kim HS
    Am J Cardiol; 2014 Nov; 114(9):1329-38. PubMed ID: 25217457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Long-Term Outcomes in Real-World Patients Between Resolute Zotarilumus-Eluting and Paclitaxel-Eluting Stents in Small Vessel.
    Kilickesmez KO; Kocaş B; Yildiz A; Coskun U; Ersanli M; Arat A; Gürmen T
    Angiology; 2016 May; 67(5):490-5. PubMed ID: 26483572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomised trials versus other limus-eluting stents and an adjusted indirect comparison.
    Cassese S; Ndrepepa G; King LA; Tada T; Fusaro M; Kastrati A
    Heart; 2012 Nov; 98(22):1632-40. PubMed ID: 22949487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
    van der Heijden LC; Kok MM; Lam MK; Danse PW; Schramm AR; Jessurun GA; Tjon Joe Gin RM; van Houwelingen KG; Hautvast RW; Linssen GC; Sen H; Löwik MM; IJzerman MJ; Doggen CJ; von Birgelen C
    Clin Res Cardiol; 2016 Mar; 105(3):206-15. PubMed ID: 26329584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Kirtane AJ; Patel R; O'Shaughnessy C; Overlie P; McLaurin B; Solomon S; Mauri L; Fitzgerald P; Popma JJ; Kandzari DE; Leon MB
    JACC Cardiovasc Interv; 2009 Oct; 2(10):967-76. PubMed ID: 19850257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
    Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
    JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries.
    Park KW; Lee JM; Kang SH; Ahn HS; Yang HM; Lee HY; Kang HJ; Koo BK; Cho J; Gwon HC; Lee SY; Chae IH; Youn TJ; Chae JK; Han KR; Yu CW; Kim HS
    J Am Coll Cardiol; 2013 Feb; 61(5):536-44. PubMed ID: 23273394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.